Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC

Sun Min Lim; Chang Gon Kim; Jii Bum Lee; Byoung Chul Cho

doi:10.1158/2159-8290.CD-21-1429

Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC

Sun Min Lim, Chang Gon Kim, Jii Bum Lee, Byoung Chul Cho

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

HER3 is ubiquitously expressed in EGFR-mutant non–small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.

Original language	English
Pages (from-to)	16-19
Number of pages	4
Journal	Cancer Discovery
Volume	12
Issue number	1
DOIs	https://doi.org/10.1158/2159-8290.CD-21-1429
Publication status	Published - 2022 Jan

Bibliographical note

Funding Information:
B.C. Cho reports grants from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint medicines, Interpark Bio Convergence Corp.; personal fees from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Med-pacto, Blueprint Medicines, TheraCanVac Inc, Gencurix Inc, Bridge-bio Therapeutics, KANAPH Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp., KANAPH Therapeutic Inc, Brigebio

Publisher Copyright:
© 2022 American Association for Cancer Research

All Science Journal Classification (ASJC) codes

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/2159-8290.CD-21-1429

Cite this

@article{d0a968af3fce4371b9e50c03fcba03d2,

title = "Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC",

abstract = "HER3 is ubiquitously expressed in EGFR-mutant non–small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, J{\"a}nne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.",

author = "Lim, {Sun Min} and Kim, {Chang Gon} and Lee, {Jii Bum} and Cho, {Byoung Chul}",

note = "Funding Information: B.C. Cho reports grants from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint medicines, Interpark Bio Convergence Corp.; personal fees from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Med-pacto, Blueprint Medicines, TheraCanVac Inc, Gencurix Inc, Bridge-bio Therapeutics, KANAPH Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp., KANAPH Therapeutic Inc, Brigebio Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research",

year = "2022",

month = jan,

doi = "10.1158/2159-8290.CD-21-1429",

language = "English",

volume = "12",

pages = "16--19",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Patritumab Deruxtecan

T2 - Paving the Way for EGFR-TKI–Resistant NSCLC

AU - Lim, Sun Min

AU - Kim, Chang Gon

AU - Lee, Jii Bum

AU - Cho, Byoung Chul

N1 - Funding Information: B.C. Cho reports grants from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint medicines, Interpark Bio Convergence Corp.; personal fees from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Med-pacto, Blueprint Medicines, TheraCanVac Inc, Gencurix Inc, Bridge-bio Therapeutics, KANAPH Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp., KANAPH Therapeutic Inc, Brigebio Publisher Copyright: © 2022 American Association for Cancer Research

PY - 2022/1

Y1 - 2022/1

N2 - HER3 is ubiquitously expressed in EGFR-mutant non–small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.

AB - HER3 is ubiquitously expressed in EGFR-mutant non–small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85123567057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123567057&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-21-1429

DO - 10.1158/2159-8290.CD-21-1429

M3 - Article

C2 - 35022206

AN - SCOPUS:85123567057

SN - 2159-8274

VL - 12

SP - 16

EP - 19

JO - Cancer Discovery

JF - Cancer Discovery

IS - 1

ER -

Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this